Roche renews partnership with Sysmex to deliver haematology testing solutions

by NASDAQ Market News January 25, 2021

NASDAQ Market News
Click here to email author

OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011

Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration

Ads